nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—SLC18A2—Parkinson's disease	0.487	0.612	CbGaD
Dextroamphetamine—SLC6A3—Parkinson's disease	0.202	0.254	CbGaD
Dextroamphetamine—CYP2D6—Parkinson's disease	0.106	0.133	CbGaD
Dextroamphetamine—SLC18A2—adrenal medulla—Parkinson's disease	0.0117	0.168	CbGeAlD
Dextroamphetamine—SLC6A2—locus ceruleus—Parkinson's disease	0.00602	0.086	CbGeAlD
Dextroamphetamine—SLC6A2—sympathetic nervous system—Parkinson's disease	0.00475	0.068	CbGeAlD
Dextroamphetamine—SLC18A2—telencephalic ventricle—Parkinson's disease	0.00467	0.0669	CbGeAlD
Dextroamphetamine—SLC6A3—telencephalic ventricle—Parkinson's disease	0.00354	0.0506	CbGeAlD
Dextroamphetamine—SLC6A2—autonomic nervous system—Parkinson's disease	0.0032	0.0457	CbGeAlD
Dextroamphetamine—SLC6A3—nerve—Parkinson's disease	0.00223	0.0319	CbGeAlD
Dextroamphetamine—TAAR1—nervous system—Parkinson's disease	0.00195	0.0279	CbGeAlD
Dextroamphetamine—TAAR1—central nervous system—Parkinson's disease	0.00188	0.0269	CbGeAlD
Dextroamphetamine—SLC6A2—nerve—Parkinson's disease	0.0018	0.0257	CbGeAlD
Dextroamphetamine—SLC6A3—hindbrain—Parkinson's disease	0.00167	0.0239	CbGeAlD
Dextroamphetamine—SLC18A2—brainstem—Parkinson's disease	0.00126	0.0181	CbGeAlD
Dextroamphetamine—ADRA1A—hindbrain—Parkinson's disease	0.00125	0.0179	CbGeAlD
Dextroamphetamine—SLC18A2—forebrain—Parkinson's disease	0.00122	0.0175	CbGeAlD
Dextroamphetamine—SLC6A3—brainstem—Parkinson's disease	0.000957	0.0137	CbGeAlD
Dextroamphetamine—SLC6A3—forebrain—Parkinson's disease	0.000923	0.0132	CbGeAlD
Dextroamphetamine—SLC18A2—medulla oblongata—Parkinson's disease	0.000882	0.0126	CbGeAlD
Dextroamphetamine—SLC18A2—midbrain—Parkinson's disease	0.000806	0.0115	CbGeAlD
Dextroamphetamine—SLC6A2—brainstem—Parkinson's disease	0.000772	0.011	CbGeAlD
Dextroamphetamine—SLC6A2—forebrain—Parkinson's disease	0.000745	0.0107	CbGeAlD
Dextroamphetamine—CYP2D6—hindbrain—Parkinson's disease	0.000737	0.0105	CbGeAlD
Dextroamphetamine—ADRA1A—brainstem—Parkinson's disease	0.000717	0.0103	CbGeAlD
Dextroamphetamine—ADRA1B—head—Parkinson's disease	0.000706	0.0101	CbGeAlD
Dextroamphetamine—SLC18A2—head—Parkinson's disease	0.000699	0.01	CbGeAlD
Dextroamphetamine—ADRA1A—forebrain—Parkinson's disease	0.000692	0.0099	CbGeAlD
Dextroamphetamine—ADRA1B—nervous system—Parkinson's disease	0.000669	0.00957	CbGeAlD
Dextroamphetamine—SLC18A2—nervous system—Parkinson's disease	0.000663	0.00948	CbGeAlD
Dextroamphetamine—ADRA1B—central nervous system—Parkinson's disease	0.000644	0.00921	CbGeAlD
Dextroamphetamine—SLC18A2—central nervous system—Parkinson's disease	0.000638	0.00912	CbGeAlD
Dextroamphetamine—SLC18A2—cerebellum—Parkinson's disease	0.000624	0.00892	CbGeAlD
Dextroamphetamine—SLC6A3—midbrain—Parkinson's disease	0.00061	0.00872	CbGeAlD
Dextroamphetamine—SLC6A3—spinal cord—Parkinson's disease	0.000595	0.00851	CbGeAlD
Dextroamphetamine—ADRA1A—cardiovascular system—Parkinson's disease	0.000586	0.00838	CbGeAlD
Dextroamphetamine—SLC6A2—medulla oblongata—Parkinson's disease	0.000538	0.0077	CbGeAlD
Dextroamphetamine—SLC6A3—head—Parkinson's disease	0.000529	0.00756	CbGeAlD
Dextroamphetamine—Lisdexamfetamine—SLC18A2—Parkinson's disease	0.000522	0.0693	CrCbGaD
Dextroamphetamine—ADRA1B—brain—Parkinson's disease	0.000511	0.00732	CbGeAlD
Dextroamphetamine—SLC18A2—brain—Parkinson's disease	0.000506	0.00724	CbGeAlD
Dextroamphetamine—SLC6A3—nervous system—Parkinson's disease	0.000501	0.00717	CbGeAlD
Dextroamphetamine—SLC6A3—central nervous system—Parkinson's disease	0.000483	0.0069	CbGeAlD
Dextroamphetamine—SLC6A3—cerebellum—Parkinson's disease	0.000472	0.00675	CbGeAlD
Dextroamphetamine—SLC6A2—head—Parkinson's disease	0.000426	0.0061	CbGeAlD
Dextroamphetamine—CYP2D6—brainstem—Parkinson's disease	0.000423	0.00604	CbGeAlD
Dextroamphetamine—Pargyline—MAOB—Parkinson's disease	0.000415	0.0551	CrCbGaD
Dextroamphetamine—Ephedrine—SLC18A2—Parkinson's disease	0.000408	0.0542	CrCbGaD
Dextroamphetamine—CYP2D6—forebrain—Parkinson's disease	0.000408	0.00583	CbGeAlD
Dextroamphetamine—SLC6A2—nervous system—Parkinson's disease	0.000404	0.00578	CbGeAlD
Dextroamphetamine—ADRA1A—head—Parkinson's disease	0.000396	0.00567	CbGeAlD
Dextroamphetamine—SLC6A2—central nervous system—Parkinson's disease	0.000389	0.00557	CbGeAlD
Dextroamphetamine—SLC6A3—brain—Parkinson's disease	0.000383	0.00548	CbGeAlD
Dextroamphetamine—ADRA1A—nervous system—Parkinson's disease	0.000376	0.00538	CbGeAlD
Dextroamphetamine—ADRA1A—central nervous system—Parkinson's disease	0.000362	0.00518	CbGeAlD
Dextroamphetamine—ADRA1A—cerebellum—Parkinson's disease	0.000354	0.00506	CbGeAlD
Dextroamphetamine—SLC6A2—brain—Parkinson's disease	0.000309	0.00442	CbGeAlD
Dextroamphetamine—L-Phenylalanine—TH—Parkinson's disease	0.000294	0.039	CrCbGaD
Dextroamphetamine—Pargyline—MAOA—Parkinson's disease	0.000291	0.0386	CrCbGaD
Dextroamphetamine—ADRA1A—brain—Parkinson's disease	0.000287	0.00411	CbGeAlD
Dextroamphetamine—Diethylpropion—SLC6A3—Parkinson's disease	0.000286	0.0379	CrCbGaD
Dextroamphetamine—Tranylcypromine—MAOB—Parkinson's disease	0.000267	0.0355	CrCbGaD
Dextroamphetamine—Amphetamine—SLC18A2—Parkinson's disease	0.000251	0.0333	CrCbGaD
Dextroamphetamine—CYP2D6—head—Parkinson's disease	0.000234	0.00334	CbGeAlD
Dextroamphetamine—Methamphetamine—SLC18A2—Parkinson's disease	0.000233	0.0309	CrCbGaD
Dextroamphetamine—Benzphetamine—SLC18A2—Parkinson's disease	0.000231	0.0306	CrCbGaD
Dextroamphetamine—Phentermine—MAOB—Parkinson's disease	0.000224	0.0297	CrCbGaD
Dextroamphetamine—CYP2D6—nervous system—Parkinson's disease	0.000221	0.00317	CbGeAlD
Dextroamphetamine—Lisdexamfetamine—SLC6A3—Parkinson's disease	0.000216	0.0287	CrCbGaD
Dextroamphetamine—CYP2D6—central nervous system—Parkinson's disease	0.000213	0.00305	CbGeAlD
Dextroamphetamine—CYP2D6—cerebellum—Parkinson's disease	0.000208	0.00298	CbGeAlD
Dextroamphetamine—Selegiline—MAOB—Parkinson's disease	0.000207	0.0275	CrCbGaD
Dextroamphetamine—Tranylcypromine—MAOA—Parkinson's disease	0.000187	0.0249	CrCbGaD
Dextroamphetamine—Phenelzine—MAOB—Parkinson's disease	0.000183	0.0242	CrCbGaD
Dextroamphetamine—Phenylpropanolamine—MAOA—Parkinson's disease	0.000176	0.0234	CrCbGaD
Dextroamphetamine—Amphetamine—MAOB—Parkinson's disease	0.000172	0.0229	CrCbGaD
Dextroamphetamine—CYP2D6—brain—Parkinson's disease	0.000169	0.00242	CbGeAlD
Dextroamphetamine—Phenylpropanolamine—DRD1—Parkinson's disease	0.00016	0.0213	CrCbGaD
Dextroamphetamine—Methamphetamine—MAOB—Parkinson's disease	0.00016	0.0212	CrCbGaD
Dextroamphetamine—Phentermine—MAOA—Parkinson's disease	0.000157	0.0208	CrCbGaD
Dextroamphetamine—Phenylpropanolamine—SLC6A3—Parkinson's disease	0.000152	0.0202	CrCbGaD
Dextroamphetamine—Pseudoephedrine—MAOA—Parkinson's disease	0.000149	0.0198	CrCbGaD
Dextroamphetamine—Selegiline—MAOA—Parkinson's disease	0.000145	0.0193	CrCbGaD
Dextroamphetamine—Phentermine—SLC6A3—Parkinson's disease	0.000135	0.018	CrCbGaD
Dextroamphetamine—Pseudoephedrine—SLC6A3—Parkinson's disease	0.000128	0.017	CrCbGaD
Dextroamphetamine—Phenelzine—MAOA—Parkinson's disease	0.000128	0.017	CrCbGaD
Dextroamphetamine—Pseudoephedrine—TNF—Parkinson's disease	0.000119	0.0158	CrCbGaD
Dextroamphetamine—Tranylcypromine—CYP2E1—Parkinson's disease	0.000116	0.0154	CrCbGaD
Dextroamphetamine—Methamphetamine—MAOA—Parkinson's disease	0.000112	0.0149	CrCbGaD
Dextroamphetamine—Amphetamine—SLC6A3—Parkinson's disease	0.000104	0.0138	CrCbGaD
Dextroamphetamine—Phenformin—CYP2D6—Parkinson's disease	0.000104	0.0138	CrCbGaD
Dextroamphetamine—Methamphetamine—SLC6A3—Parkinson's disease	9.65e-05	0.0128	CrCbGaD
Dextroamphetamine—Benzphetamine—SLC6A3—Parkinson's disease	9.57e-05	0.0127	CrCbGaD
Dextroamphetamine—Benzyl alcohol—CYP2E1—Parkinson's disease	9.34e-05	0.0124	CrCbGaD
Dextroamphetamine—Selegiline—CYP2E1—Parkinson's disease	8.97e-05	0.0119	CrCbGaD
Dextroamphetamine—Tranylcypromine—CYP2D6—Parkinson's disease	8.49e-05	0.0113	CrCbGaD
Dextroamphetamine—Phenelzine—CYP2E1—Parkinson's disease	7.9e-05	0.0105	CrCbGaD
Dextroamphetamine—Amphetamine—DRD2—Parkinson's disease	7.74e-05	0.0103	CrCbGaD
Dextroamphetamine—Phentermine—CYP2D6—Parkinson's disease	7.11e-05	0.00945	CrCbGaD
Dextroamphetamine—Benzyl alcohol—CYP2D6—Parkinson's disease	6.86e-05	0.00911	CrCbGaD
Dextroamphetamine—Pseudoephedrine—CYP2D6—Parkinson's disease	6.74e-05	0.00896	CrCbGaD
Dextroamphetamine—Selegiline—CYP2D6—Parkinson's disease	6.58e-05	0.00874	CrCbGaD
Dextroamphetamine—Nateglinide—CYP2D6—Parkinson's disease	5.88e-05	0.00781	CrCbGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DGKQ—Parkinson's disease	5.84e-05	0.000461	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—CYCS—Parkinson's disease	5.79e-05	0.000457	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	5.77e-05	0.000456	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—CP—Parkinson's disease	5.7e-05	0.00045	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—COMT—Parkinson's disease	5.69e-05	0.000449	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—FGB—Parkinson's disease	5.66e-05	0.000447	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—GRM5—Parkinson's disease	5.66e-05	0.000447	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—HTR2A—Parkinson's disease	5.65e-05	0.000446	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—MAOA—Parkinson's disease	5.65e-05	0.000446	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—Parkinson's disease	5.65e-05	0.000446	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HTR1A—Parkinson's disease	5.63e-05	0.000445	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—EDN1—Parkinson's disease	5.61e-05	0.000443	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TAC1—Parkinson's disease	5.55e-05	0.000438	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—HTR2A—Parkinson's disease	5.52e-05	0.000436	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC18A2—Parkinson's disease	5.48e-05	0.000433	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	5.48e-05	0.000433	CbGpPWpGaD
Dextroamphetamine—Amphetamine—CYP2D6—Parkinson's disease	5.47e-05	0.00726	CrCbGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PPP1R1B—Parkinson's disease	5.46e-05	0.000431	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD1—Parkinson's disease	5.44e-05	0.000429	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—ADORA2A—Parkinson's disease	5.42e-05	0.000428	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	5.41e-05	0.000427	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	5.41e-05	0.000427	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	5.4e-05	0.000426	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DGKQ—Parkinson's disease	5.3e-05	0.000418	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—GPR37—Parkinson's disease	5.3e-05	0.000418	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	5.3e-05	0.000418	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD3—Parkinson's disease	5.27e-05	0.000416	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	5.22e-05	0.000412	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	5.22e-05	0.000412	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	5.13e-05	0.000405	CbGpPWpGaD
Dextroamphetamine—Methamphetamine—CYP2D6—Parkinson's disease	5.07e-05	0.00673	CrCbGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—CP—Parkinson's disease	5.05e-05	0.000398	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	5.04e-05	0.000397	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—Parkinson's disease	5.02e-05	0.000396	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—GRK5—Parkinson's disease	4.98e-05	0.000393	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Parkinson's disease	4.94e-05	0.00039	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ADRBK1—Parkinson's disease	4.92e-05	0.000388	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—HTR2A—Parkinson's disease	4.91e-05	0.000387	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PPP1R1B—Parkinson's disease	4.85e-05	0.000383	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	4.83e-05	0.000381	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—ADORA2A—Parkinson's disease	4.81e-05	0.00038	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HTR7—Parkinson's disease	4.77e-05	0.000376	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD2—Parkinson's disease	4.77e-05	0.000376	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP2E1—Parkinson's disease	4.73e-05	0.000374	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—HTR1A—Parkinson's disease	4.7e-05	0.000371	CbGpPWpGaD
Dextroamphetamine—Selegiline—ABCB1—Parkinson's disease	4.7e-05	0.00624	CrCbGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP2E1—Parkinson's disease	4.67e-05	0.000369	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	4.64e-05	0.000366	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	4.64e-05	0.000366	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—TAC1—Parkinson's disease	4.63e-05	0.000365	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD1—Parkinson's disease	4.54e-05	0.000358	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—GRK5—Parkinson's disease	4.52e-05	0.000357	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—GRM4—Parkinson's disease	4.47e-05	0.000353	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—GRK5—Parkinson's disease	4.42e-05	0.000349	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD3—Parkinson's disease	4.4e-05	0.000347	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Parkinson's disease	4.39e-05	0.000346	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	4.27e-05	0.000337	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VPS35—Parkinson's disease	4.25e-05	0.000336	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PENK—Parkinson's disease	4.23e-05	0.000334	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	4.18e-05	0.00033	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—HTR1A—Parkinson's disease	4.18e-05	0.00033	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—TAC1—Parkinson's disease	4.11e-05	0.000325	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	4.06e-05	0.00032	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—GRM4—Parkinson's disease	4.06e-05	0.00032	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD1—Parkinson's disease	4.03e-05	0.000318	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—GRK5—Parkinson's disease	4.02e-05	0.000317	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IGF2—Parkinson's disease	3.99e-05	0.000315	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—HTR7—Parkinson's disease	3.98e-05	0.000314	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD2—Parkinson's disease	3.98e-05	0.000314	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—GRM4—Parkinson's disease	3.97e-05	0.000313	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—COMT—Parkinson's disease	3.92e-05	0.00031	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD3—Parkinson's disease	3.91e-05	0.000308	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTP1—Parkinson's disease	3.9e-05	0.000308	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—CYCS—Parkinson's disease	3.9e-05	0.000308	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—MAOA—Parkinson's disease	3.9e-05	0.000307	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PDYN—Parkinson's disease	3.87e-05	0.000306	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—COMT—Parkinson's disease	3.87e-05	0.000305	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IGF1R—Parkinson's disease	3.86e-05	0.000305	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTP1—Parkinson's disease	3.85e-05	0.000304	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PENK—Parkinson's disease	3.85e-05	0.000304	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—EDN1—Parkinson's disease	3.82e-05	0.000301	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	3.79e-05	0.000299	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VPS35—Parkinson's disease	3.78e-05	0.000298	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PENK—Parkinson's disease	3.76e-05	0.000297	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	3.71e-05	0.000293	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	3.66e-05	0.000289	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—GRM4—Parkinson's disease	3.6e-05	0.000284	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—GRM5—Parkinson's disease	3.6e-05	0.000284	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTM1—Parkinson's disease	3.59e-05	0.000283	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTM1—Parkinson's disease	3.54e-05	0.000279	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD2—Parkinson's disease	3.53e-05	0.000279	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—HTR7—Parkinson's disease	3.53e-05	0.000279	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DGKQ—Parkinson's disease	3.53e-05	0.000278	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GPR37—Parkinson's disease	3.53e-05	0.000278	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PDYN—Parkinson's disease	3.52e-05	0.000278	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NGF—Parkinson's disease	3.51e-05	0.000277	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—CYCS—Parkinson's disease	3.45e-05	0.000273	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PDYN—Parkinson's disease	3.44e-05	0.000272	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PENK—Parkinson's disease	3.42e-05	0.00027	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	3.39e-05	0.000267	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HTR2A—Parkinson's disease	3.34e-05	0.000263	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—GRM5—Parkinson's disease	3.27e-05	0.000258	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	3.25e-05	0.000257	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	3.25e-05	0.000256	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PPP1R1B—Parkinson's disease	3.22e-05	0.000254	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—GRM5—Parkinson's disease	3.2e-05	0.000252	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—EDN1—Parkinson's disease	3.18e-05	0.000251	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GPR37—Parkinson's disease	3.13e-05	0.000247	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DGKQ—Parkinson's disease	3.13e-05	0.000247	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PDYN—Parkinson's disease	3.12e-05	0.000247	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—APOE—Parkinson's disease	3.1e-05	0.000245	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ADORA2A—Parkinson's disease	3.06e-05	0.000242	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	3e-05	0.000237	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—GRM5—Parkinson's disease	2.9e-05	0.000229	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	2.88e-05	0.000227	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PPP1R1B—Parkinson's disease	2.86e-05	0.000226	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—EDN1—Parkinson's disease	2.83e-05	0.000223	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RIT2—Parkinson's disease	2.82e-05	0.000222	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—HTR2A—Parkinson's disease	2.79e-05	0.00022	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ADORA2A—Parkinson's disease	2.78e-05	0.000219	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ADORA2A—Parkinson's disease	2.72e-05	0.000215	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GRK5—Parkinson's disease	2.67e-05	0.000211	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—HTR1A—Parkinson's disease	2.66e-05	0.00021	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—INS—Parkinson's disease	2.65e-05	0.000209	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—TAC1—Parkinson's disease	2.62e-05	0.000206	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD1—Parkinson's disease	2.57e-05	0.000203	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MCCC1—Parkinson's disease	2.54e-05	0.000201	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ND3—Parkinson's disease	2.54e-05	0.000201	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RIT2—Parkinson's disease	2.5e-05	0.000198	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD3—Parkinson's disease	2.48e-05	0.000196	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—HTR2A—Parkinson's disease	2.47e-05	0.000195	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ADORA2A—Parkinson's disease	2.47e-05	0.000195	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HTR1A—Parkinson's disease	2.41e-05	0.00019	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GRM4—Parkinson's disease	2.4e-05	0.000189	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TALDO1—Parkinson's disease	2.39e-05	0.000189	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—OMD—Parkinson's disease	2.39e-05	0.000189	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—TAC1—Parkinson's disease	2.38e-05	0.000188	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GRK5—Parkinson's disease	2.37e-05	0.000187	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—HTR1A—Parkinson's disease	2.36e-05	0.000186	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD1—Parkinson's disease	2.33e-05	0.000184	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—TAC1—Parkinson's disease	2.32e-05	0.000183	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ADRBK1—Parkinson's disease	2.32e-05	0.000183	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD1—Parkinson's disease	2.28e-05	0.00018	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PENK—Parkinson's disease	2.27e-05	0.000179	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAG—Parkinson's disease	2.27e-05	0.000179	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NDUFB11—Parkinson's disease	2.27e-05	0.000179	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD3—Parkinson's disease	2.26e-05	0.000178	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD2—Parkinson's disease	2.25e-05	0.000177	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—HTR7—Parkinson's disease	2.25e-05	0.000177	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD3—Parkinson's disease	2.21e-05	0.000174	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GCH1—Parkinson's disease	2.16e-05	0.000171	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HTR1A—Parkinson's disease	2.14e-05	0.000169	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GRM4—Parkinson's disease	2.13e-05	0.000168	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—TAC1—Parkinson's disease	2.11e-05	0.000167	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ADRBK1—Parkinson's disease	2.11e-05	0.000166	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PDYN—Parkinson's disease	2.08e-05	0.000164	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD1—Parkinson's disease	2.07e-05	0.000163	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ADRBK1—Parkinson's disease	2.06e-05	0.000163	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD2—Parkinson's disease	2.04e-05	0.000161	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HTR7—Parkinson's disease	2.04e-05	0.000161	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PENK—Parkinson's disease	2.02e-05	0.000159	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAG—Parkinson's disease	2.02e-05	0.000159	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD3—Parkinson's disease	2e-05	0.000158	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD2—Parkinson's disease	2e-05	0.000158	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—HTR7—Parkinson's disease	2e-05	0.000158	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CASP3—Parkinson's disease	1.97e-05	0.000156	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL6—Parkinson's disease	1.96e-05	0.000155	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GFAP—Parkinson's disease	1.95e-05	0.000154	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GRM5—Parkinson's disease	1.93e-05	0.000152	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—FBP1—Parkinson's disease	1.93e-05	0.000152	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GBA—Parkinson's disease	1.93e-05	0.000152	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—DBH—Parkinson's disease	1.93e-05	0.000152	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ADRBK1—Parkinson's disease	1.87e-05	0.000148	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PDYN—Parkinson's disease	1.85e-05	0.000146	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MAPK8—Parkinson's disease	1.81e-05	0.000143	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD2—Parkinson's disease	1.81e-05	0.000143	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HTR7—Parkinson's disease	1.81e-05	0.000143	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—EDN1—Parkinson's disease	1.8e-05	0.000142	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GFAP—Parkinson's disease	1.74e-05	0.000137	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GRM5—Parkinson's disease	1.72e-05	0.000135	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	1.71e-05	0.000135	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGF20—Parkinson's disease	1.69e-05	0.000134	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADORA2A—Parkinson's disease	1.64e-05	0.00013	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—EDN1—Parkinson's disease	1.63e-05	0.000129	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—EDN1—Parkinson's disease	1.6e-05	0.000126	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—HTR2A—Parkinson's disease	1.57e-05	0.000124	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	1.52e-05	0.00012	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—INSR—Parkinson's disease	1.52e-05	0.00012	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGF20—Parkinson's disease	1.5e-05	0.000119	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADORA2A—Parkinson's disease	1.46e-05	0.000115	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—EDN1—Parkinson's disease	1.45e-05	0.000115	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGB—Parkinson's disease	1.43e-05	0.000113	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HTR2A—Parkinson's disease	1.43e-05	0.000113	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HTR1A—Parkinson's disease	1.43e-05	0.000112	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—DDC—Parkinson's disease	1.42e-05	0.000112	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TAC1—Parkinson's disease	1.4e-05	0.000111	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—HTR2A—Parkinson's disease	1.4e-05	0.00011	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD1—Parkinson's disease	1.38e-05	0.000109	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—INSR—Parkinson's disease	1.35e-05	0.000106	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTA4—Parkinson's disease	1.34e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD3—Parkinson's disease	1.33e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGB—Parkinson's disease	1.27e-05	0.0001	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HTR2A—Parkinson's disease	1.27e-05	0.0001	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HTR1A—Parkinson's disease	1.27e-05	9.99e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TAC1—Parkinson's disease	1.25e-05	9.84e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADRBK1—Parkinson's disease	1.24e-05	9.82e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD1—Parkinson's disease	1.22e-05	9.65e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD2—Parkinson's disease	1.21e-05	9.51e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HTR7—Parkinson's disease	1.21e-05	9.51e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	1.2e-05	9.5e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MAOB—Parkinson's disease	1.19e-05	9.4e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD3—Parkinson's disease	1.18e-05	9.35e-05	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6—Parkinson's disease	1.16e-05	9.14e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADRBK1—Parkinson's disease	1.11e-05	8.73e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HTR7—Parkinson's disease	1.07e-05	8.45e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD2—Parkinson's disease	1.07e-05	8.45e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF2—Parkinson's disease	1.01e-05	7.97e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF1R—Parkinson's disease	9.77e-06	7.71e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EDN1—Parkinson's disease	9.65e-06	7.62e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF2—Parkinson's disease	8.97e-06	7.08e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NGF—Parkinson's disease	8.87e-06	7e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CTGF—Parkinson's disease	8.69e-06	6.86e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF1R—Parkinson's disease	8.68e-06	6.85e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EDN1—Parkinson's disease	8.57e-06	6.77e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HTR2A—Parkinson's disease	8.44e-06	6.66e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	8.1e-06	6.39e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NQO1—Parkinson's disease	8.01e-06	6.32e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TH—Parkinson's disease	7.89e-06	6.23e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NGF—Parkinson's disease	7.88e-06	6.22e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APOE—Parkinson's disease	7.85e-06	6.2e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYCS—Parkinson's disease	7.58e-06	5.98e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HTR2A—Parkinson's disease	7.5e-06	5.92e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APOE—Parkinson's disease	6.97e-06	5.5e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—COMT—Parkinson's disease	6.71e-06	5.29e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—INS—Parkinson's disease	6.71e-06	5.29e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTP1—Parkinson's disease	6.68e-06	5.27e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MAOA—Parkinson's disease	6.66e-06	5.26e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HMOX1—Parkinson's disease	6.59e-06	5.2e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCB1—Parkinson's disease	6.32e-06	4.99e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTM1—Parkinson's disease	6.14e-06	4.84e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—INS—Parkinson's disease	5.96e-06	4.7e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GPX1—Parkinson's disease	5.88e-06	4.64e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MTHFR—Parkinson's disease	5.42e-06	4.28e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APOE—Parkinson's disease	5.05e-06	3.98e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASP3—Parkinson's disease	4.99e-06	3.94e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6—Parkinson's disease	4.96e-06	3.91e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAPK8—Parkinson's disease	4.59e-06	3.62e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASP3—Parkinson's disease	4.43e-06	3.5e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6—Parkinson's disease	4.41e-06	3.48e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—INS—Parkinson's disease	4.31e-06	3.4e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAPK8—Parkinson's disease	4.08e-06	3.22e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6—Parkinson's disease	2.93e-06	2.31e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6—Parkinson's disease	2.6e-06	2.05e-05	CbGpPWpGaD
